|. Reports, N. Ferrara, H. P. Gerber, and J. Lecouter, The biology of VEGF and its receptors, Nat Med, vol.9, pp.669-676, 2003.

N. Ferrara, Vascular endothelial growth factor: basic science and clinical progress, Endocr Rev, vol.25, pp.581-611, 2004.

C. Abou-faycal, A. S. Hatat, S. Gazzeri, and B. Eymin, Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy, Int J Mol Sci, vol.18, p.383, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02337324

C. Abou-faycal, The sVEGFR1-i13 splice variant regulates a beta1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma, Br J Cancer, vol.118, pp.1596-1608, 2018.

J. A. Meyerhardt, Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer, PLoS One, vol.7, p.38231, 2012.

D. G. Duda, Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer, Oncologist, vol.15, pp.577-583, 2010.

C. G. Willett, Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study, J Clin Oncol, vol.27, pp.3020-3026, 2009.

F. T. Wu, A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use, J Cell Mol Med, vol.14, pp.528-552, 2010.

R. L. Kendall and K. A. Thomas, Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor, Proc Natl Acad Sci, vol.90, pp.10705-10709, 1993.

K. Inoue, Y. Ozeki, T. Suganuma, Y. Sugiura, and S. Tanaka, Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression, Cancer, vol.79, pp.206-213, 1997.

R. L. Kendall, G. Wang, and K. A. Thomas, Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR, Biochem Biophys Res Commun, vol.226, pp.324-328, 1996.

C. K. Goldman, Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate, Proc Natl Acad Sci, vol.95, pp.8795-8800, 1998.

A. Orecchia, Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin, J Cell Sci, vol.116, pp.3479-3489, 2003.

S. Soro, A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through alpha5beta1 integrin, Blood, vol.111, pp.3479-3488, 2008.

S. Ahmad, Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis, Vasc Cell, vol.3, p.15, 2011.

T. Saito, VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing, FEBS Lett, vol.587, pp.2179-2185, 2013.

J. N. Boeckel, Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1, Proc Natl Acad Sci, vol.108, pp.3276-3281, 2011.

T. Kangsamaksin, NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth, Cancer Discov, vol.5, pp.182-197, 2015.

A. Boudria, VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a beta1 integrin/VEGFR autocrine loop, Epub Ahead of Print, 2018.

D. Zhao, VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2, Oncogene, vol.34, pp.3107-3119, 2015.

D. Tao, Genetic alteration profiling of patients with resected squamous cell lung carcinomas, Oncotarget, pp.36590-36601, 2016.

X. Xu, The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2, Genes Dev, vol.28, pp.1929-1939, 2014.

J. C. Long and J. F. Caceres, The SR protein family of splicing factors: master regulators of gene expression, Biochem J, vol.417, pp.15-27, 2009.

S. Gout, Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma, PLoS One, vol.7, p.46539, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02337424

M. Raponi, Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung, Cancer Res, vol.66, pp.7466-7472, 2006.

M. Li and J. C. Belmonte, Ground rules of the pluripotency gene regulatory network, Nat Rev Genet, vol.18, pp.180-191, 2017.

T. Yamaguchi, Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis, Cancer Sci, vol.98, pp.405-410, 2007.

M. Toi, Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer, Int J Cancer, vol.98, pp.14-18, 2002.

, Scientific RepoRts |, vol.9, 2019.

K. Lamszus, Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A, Clin Cancer Res, vol.9, pp.1399-1405, 2003.

N. Ilhan, N. Ilhan, and F. Deveci, Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types, Clin Biochem, vol.37, pp.840-845, 2004.

A. X. Zhu, A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer, Clin Cancer Res, vol.19, pp.6614-6623, 2013.

S. M. Tolaney, Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients, Proc Natl Acad Sci, vol.112, pp.14325-14330, 2015.

A. L. Harris, Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy, Clin Cancer Res, vol.7, 1992.

R. S. Heist, Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer, Proc Natl Acad Sci, vol.112, pp.1547-1552, 2015.

S. Kopetz, Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance, J Clin Oncol, vol.28, pp.453-459, 2010.

C. P. Thomas, A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia, J Clin Endocrinol Metab, vol.94, pp.2524-2530, 2009.

K. R. Palmer, Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production, Biol Reprod, vol.94, p.59, 2016.

G. Zhao, The Soluble VEGF Receptor sFlt-1 Contributes to Impaired Neovascularization in Aged Mice, Aging Dis, vol.8, pp.287-300, 2017.

Y. Lu, Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells, Cell Stem Cell, vol.15, pp.92-101, 2014.

M. Larrayoz, Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype, EMBO Mol Med, vol.6, pp.539-550, 2014.

G. Merdzhanova, E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35, Cell Death Differ, vol.15, pp.1815-1823, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00360967

W. D. Travis, International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma, J Thorac Oncol, vol.6, pp.244-285, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-00561753

C. Salon, E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short), Cell Death Differ, vol.13, pp.260-272, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00172959